These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37936966)

  • 1. When a pandemic and epidemic collide: Lessons learned about how system barriers can interrupt implementation of addiction research.
    Sharp A; Carlson M; Vroom EB; Rigg K; Hills H; Harding C; Moore K; Schuman-Olivier Z
    Implement Res Pract; 2023; 4():26334895231205890. PubMed ID: 37936966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
    O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the feasibility, usability and acceptability of the
    Janzow GE; Harding C; Flores M; Borodovsky J; Steinkamp J; Marsch LA; Schuman-Olivier Z
    Drug Alcohol Depend Rep; 2022 Jun; 3():100045. PubMed ID: 36845988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.
    Schuman-Olivier Z; Borodovsky JT; Steinkamp J; Munir Q; Butler K; Greene MA; Goldblatt J; Xie HY; Marsch LA
    Addict Sci Clin Pract; 2018 Sep; 13(1):21. PubMed ID: 30249279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial.
    Hser YI; Ober AJ; Dopp AR; Lin C; Osterhage KP; Clingan SE; Mooney LJ; Curtis ME; Marsch LA; McLeman B; Hichborn E; Lester LS; Baldwin LM; Liu Y; Jacobs P; Saxon AJ
    Addict Sci Clin Pract; 2021 Apr; 16(1):24. PubMed ID: 33879260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study.
    Miller WA; Gordon AJ; Clothier BA; Ackland PE; Bounthavong M; Garcia C; Kenny ME; Noorbaloochi S; Hagedorn HJ
    Implement Res Pract; 2023; 4():26334895231199463. PubMed ID: 37790176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
    Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
    Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobile service delivery in response to the opioid epidemic in Philadelphia.
    Stewart RE; Christian HP; Cardamone NC; Abrams C; Drob C; Mandell DS; Metzger D; Lowenstein M
    Addict Sci Clin Pract; 2023 Nov; 18(1):71. PubMed ID: 38031174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative.
    Krawczyk N; Bandara S; Merritt S; Shah H; Duncan A; McEntee B; Schiff M; Ahmad NJ; Whaley S; Latimore A; Saloner B
    Addict Sci Clin Pract; 2022 Jun; 17(1):30. PubMed ID: 35655293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
    Bogan C; Jennings L; Haynes L; Barth K; Moreland A; Oros M; Goldsby S; Lane S; Funcell C; Brady K
    J Subst Abuse Treat; 2020 Mar; 112S():73-78. PubMed ID: 32220414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment.
    McNeely J; Troxel AB; Kunins HV; Shelley D; Lee JD; Walley A; Weinstein ZM; Billings J; Davis NJ; Marcello RK; Schackman BR; Barron C; Bergmann L
    Addict Sci Clin Pract; 2019 Feb; 14(1):5. PubMed ID: 30777122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose.
    Klemperer EM; Wreschnig L; Crocker A; King-Mohr J; Ramniceanu A; Brooklyn JR; Peck KR; Rawson RA; Evans EA
    J Subst Use Addict Treat; 2023 Sep; 152():209103. PubMed ID: 37311520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.
    Gregory HM; Hill VM; Parker RW
    Cureus; 2021 Nov; 13(11):e19870. PubMed ID: 34976492
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.